Granulocyte colony-stimulating factor plus pentoxifylline increases short-term survival in patients with severe alcoholic hepatitis: a network meta-analysis

References

• Rambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C. Systematic review: glucocorticosteroids for alcoholic hepatitis–a Cochrane Hepato-Biliary group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther. 2008;27:1167–78. doi:10.1111/j.1365-2036.2008.03685.x. Epub 2008/03/28; PubMed PMID: 18363896.
   PubMed Web of Science ®Google Scholar
• Casanova J, Bataller R. Alcoholic hepatitis: prognosis and treatment. Gastroenterol Hepatol. 2014;37:262–68. doi:10.1016/j.gastrohep.2014.02.001. Epub 2014/03/25; PubMed PMID: 24656653.
   PubMed Web of Science ®Google Scholar
• Phillips M, Curtis H, Portmann B, Donaldson N, Bomford A, O’Grady J. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis–a randomised clinical trial. J Hepatol. 2006;44:784–90. doi:10.1016/j.jhep.2005.11.039. Epub 2006/02/14; PubMed PMID: 16469404.
   PubMed Web of Science ®Google Scholar
• De BK, Gangopadhyay S, Dutta D, Baksi SD, Pani A, Ghosh P. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol. 2009;15:1613–19. doi:10.3748/wjg.15.1613. Epub 2009/04/03; PubMed PMID: 19340904; PubMed Central PMCID: PMC2669113.
   PubMed Web of Science ®Google Scholar
• Moreno C, Langlet P, Hittelet A, Lasser L, Degre D, Evrard S, Colle I, Lemmers A, Devière J, Le Moine O, et al. Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial. J Hepatol. 2010;53:1117–22. doi:10.1016/j.jhep.2010.05.030. Epub 2010/08/31; PubMed PMID: 20801542.
   PubMed Web of Science ®Google Scholar
• Nguyen-Khac E, Thevenot T, Piquet MA, Benferhat S, Goria O, Chatelain D, Tramier B, Dewaele F, Ghrib S, Rudler M, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med. 2011;365:1781–89. doi:10.1056/NEJMoa1101214. Epub 2011/11/11; PubMed PMID: 22070475.
   PubMed Web of Science ®Google Scholar
• Sidhu SS, Goyal O, Singla P, Gupta D, Sood A, Chhina RS, Soni RK. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Dig Dis Sci. 2012;57:1664–71. doi:10.1007/s10620-012-2097-4. Epub 2012/03/06; PubMed PMID: 22388710.
   PubMed Web of Science ®Google Scholar
• De B, Mandal S, Sau D, Mani S, Chatterjee S, Mondal S, Bhattacharya K, et al. Pentoxifylline plus prednisolone versus pentoxifylline only for severe alcoholic hepatitis: a randomized controlled clinical trial. Ann Med Health Sci Res. 2014;4:810–16. doi:10.4103/2141-9248.141562. Epub 2014/10/21; PubMed PMID: 25328799; PubMed Central PMCID: PMC4199180.
   PubMedGoogle Scholar
• Singh V, Sharma AK, Narasimhan RL, Bhalla A, Sharma N, Sharma R. Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study. Am J Gastroenterol. 2014;109:1417–23. doi:10.1038/ajg.2014.154. Epub 2014/06/18; PubMed PMID: 24935272.
   PubMed Web of Science ®Google Scholar
• Higuera-de la Tijera F, Servin-Caamano AI, Serralde-Zuniga AE, Cruz-Herrera J, Perez-Torres E, Abdo-Francis JM, Salas-Gordillo F, Perez-Hernandez JL. Metadoxine improves the three- and six-month survival rates in patients with severe alcoholic hepatitis. World J Gastroenterol. 2015;21:4975–85. doi:10.3748/wjg.v21.i16.4975. Epub 2015/05/07; PubMed PMID: 25945012; PubMed Central PMCID: PMC4408471.
   PubMed Web of Science ®Google Scholar
• Tkachenko P, Maevskaya M, Pavlov A, Komkova I, Pavlov C, Ivashkin V. Prednisolone plus S-adenosil-L-methionine in severe alcoholic hepatitis. Hepatol Int. 2016;10:983–87. doi:10.1007/s12072-016-9751-4. Epub 2016/10/28; PubMed PMID: 27337960.
   PubMed Web of Science ®Google Scholar
• Singh V, Keisham A, Bhalla A, Sharma N, Agarwal R, Sharma R, Singh A. Efficacy of granulocyte colony-stimulating factor and N-Acetylcysteine therapies in patients with severe alcoholic hepatitis. Clin Gastroenterol Hepatol. 2018;16:1650–6 e2. doi:10.1016/j.cgh.2018.01.040. Epub 2018/02/03; PubMed PMID: 29391265.
   PubMed Web of Science ®Google Scholar
• Shasthry SM, Sharma MK, Shasthry V, Pande A, Sarin SK. Efficacy of granulocyte colony-stimulating factor in the management of steroid-nonresponsive severe alcoholic hepatitis: a Double-blind randomized controlled trial. Hepatology. 2019;70:802–11. doi:10.1002/hep.30516. Epub 2019/01/22; PubMed PMID: 30664267.
   PubMed Web of Science ®Google Scholar
• Mathurin P. Early liver transplantation for acute alcoholic hepatitis: we can’t say no. J Hepatol. 2021;75:718–22. doi:10.1016/j.jhep.2021.05.019. Epub 2021/06/01; PubMed PMID: 34058297.
   PubMed Web of Science ®Google Scholar
• Im GY, Kim-Schluger L, Shenoy A, Schubert E, Goel A, Friedman SL, Florman S, Schiano TD. Early liver transplantation for severe alcoholic hepatitis in the United States–A single-center experience. Am J Transplant. 2016;16:841–49. doi:10.1111/ajt.13586. Epub 2015/12/29; PubMed PMID: 26710309.
   PubMed Web of Science ®Google Scholar
• Louvet A, Thursz MR, Kim DJ, Labreuche J, Atkinson SR, Sidhu SS, O'Grady JG, et al. Corticosteroids reduce risk of death within 28 days for patients with severe alcoholic hepatitis, compared with pentoxifylline or Placebo-a meta-analysis of individual data from controlled trials. Gastroenterology. 2018;155:458–68 e8. doi:10.1053/j.gastro.2018.05.011. Epub 2018/05/09; PubMed PMID: 29738698.
   PubMed Web of Science ®Google Scholar
• Hmoud BS, Patel K, Bataller R, Singal AK. Corticosteroids and occurrence of and mortality from infections in severe alcoholic hepatitis: a meta-analysis of randomized trials. Liver Int. 2016;36:721–28. doi:10.1111/liv.12939. Epub 2015/08/19; PubMed PMID: 26279269.
   PubMed Web of Science ®Google Scholar
• Singh S, Murad MH, Chandar AK, Bongiorno CM, Singal AK, Atkinson SR, Thursz MR, et al. Comparative effectiveness of pharmacological interventions for severe alcoholic hepatitis: a systematic review and network meta-analysis. Gastroenterology. 2015;149:958–70 e12. doi:10.1053/j.gastro.2015.06.006. Epub 2015/06/21; PubMed PMID: 26091937.
   PubMed Web of Science ®Google Scholar
• Porter HP, Simon FR, Pope CE, 2nd, Volwiler W, Fenster LF. Corticosteroid therapy in severe alcoholic hepatitis. A double-blind drug trial. N Engl J Med. 1971;284:1350–55. doi:10.1056/NEJM197106172842404. Epub 1971/06/17; PubMed PMID: 4930603.
   PubMed Web of Science ®Google Scholar
• Campra JL, Hamlin EM Jr., Kirshbaum RJ, Olivier M, Redeker AG, Reynolds TB. Prednisone therapy of acute alcoholic hepatitis. Report of a controlled trial. Ann Intern Med. 1973;79:625–31. doi:10.7326/0003-4819-79-5-625. Epub 1973/11/01; PubMed PMID: 4751740.
   PubMed Web of Science ®Google Scholar
• Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr., Mezey E, White RI Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology. 1978;75:193–99. doi:10.1016/0016-5085(78)90401-8. Epub 1978/08/01; PubMed PMID: 352788.
   PubMed Web of Science ®Google Scholar
• Depew W, Boyer T, Omata M, Redeker A, Reynolds T. Double-blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy. Gastroenterology. 1980;78:524–29. doi: 10.1016/0016-5085(80)90867-7. Epub 1980/03/01; PubMed PMID: 6985881.
   PubMed Web of Science ®Google Scholar
• Halle P, Pare P, Kaptein E, Kanel G, Redeker AG, Reynolds TB. Double-blind, controlled trial of propylthiouracil in patients with severe acute alcoholic hepatitis. Gastroenterology. 1982;82:925–31. doi: 10.1016/S0016-5085(82)80257-6. Epub 1982/05/01; PubMed PMID: 7037524.
   PubMed Web of Science ®Google Scholar
• Theodossi A, Eddleston AL, Williams R. Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis. Gut. 1982;23:75–79. doi:10.1136/gut.23.1.75. Epub 1982/01/01; PubMed PMID: 7035299; PubMed Central PMCID: PMC1419581.
   PubMed Web of Science ®Google Scholar
• Carithers RL Jr., Herlong HF, Diehl AM, Shaw EW, Combes B, Fallon HJ, Maddrey WC. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med. 1989;110:685–90. Epub 1989/05/01; PubMed PMID: 2648927.
   PubMed Web of Science ®Google Scholar
• Akriviadis EA, Steindel H, Pinto PC, Fong TL, Kanel G, Reynolds TB, Gupta S. Failure of colchicine to improve short-term survival in patients with alcoholic hepatitis. Gastroenterology. 1990;99:811–18. doi:10.1016/0016-5085(90)90973-5. Epub 1990/09/01; PubMed PMID: 2199290.
   PubMed Web of Science ®Google Scholar
• Bird G, Lau JY, Koskinas J, Wicks C, Williams R. Insulin and glucagon infusion in acute alcoholic hepatitis: a prospective randomized controlled trial. Hepatology. 1991;14:1097–101. doi:10.1002/hep.1840140625. Epub 1991/12/01. PubMed PMID: 1959860.
   PubMed Web of Science ®Google Scholar
• Ramond MJ, Poynard T, Rueff B, Mathurin P, Theodore C, Chaput JC, Benhamou JP. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med. 1992;326:507–12. doi:10.1056/NEJM199202203260802. Epub 1992/02/20 PubMed PMID: 1531090.
   PubMed Web of Science ®Google Scholar
• Trinchet JC, Balkau B, Poupon RE, Heintzmann F, Callard P, Gotheil C, Grange J-D, Vetter D, Pauwels A, Labadie H, et al. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon: a multicenter sequential trial. Hepatology. 1992;15:76–81. doi:10.1002/hep.1840150115. Epub 1992/01/01; PubMed PMID: 1727803.
   PubMed Web of Science ®Google Scholar
• Bird GL, Prach AT, McMahon AD, Forrest JA, Mills PR, Danesh BJ. Randomised controlled double-blind trial of the calcium channel antagonist amlodipine in the treatment of acute alcoholic hepatitis. J Hepatol. 1998;28:194–98. doi:10.1016/0168-8278(88)80005-9. Epub 1998/03/26; PubMed PMID: 9514531.
   PubMed Web of Science ®Google Scholar
• Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:1637–48. doi:10.1053/gast.2000.20189. Epub 2000/12/13; PubMed PMID: 11113085.
   PubMed Web of Science ®Google Scholar
• Spahr L, Rubbia-Brandt L, Frossard JL, Giostra E, Rougemont AL, Pugin J, Fischer M, Egger H, Hadengue A. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol. 2002;37:448–55. doi:10.1016/s0168-8278(02)00230-1. Epub 2002/09/10; PubMed PMID: 12217597.
   PubMed Web of Science ®Google Scholar
• Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA, Davion T, Oberti F, Broët P, Emilie D, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology. 2004;39:1390–97. doi:10.1002/hep.20206. Epub 2004/05/04; PubMed PMID: 15122768.
   PubMed Web of Science ®Google Scholar
• Sidhu SS, Goyal O, Singla M, Bhatia KL, Chhina RS, Sood A. Pentoxifylline in severe alcoholic hepatitis: a prospective, randomised trial. J Assoc Physicians India. 2012;60:20–22. Epub 2012/10/04; PubMed PMID: 23029716.
   PubMedGoogle Scholar
• Mathurin P, Louvet A, Duhamel A, Nahon P, Carbonell N, Boursier J, Anty R, Diaz E, Thabut D, Moirand R, et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA. 2013;310:1033–41. doi:10.1001/jama.2013.276300. Epub 2013/09/13; PubMed PMID: 24026598.
   PubMed Web of Science ®Google Scholar
• Park SH, Kim DJ, Kim YS, Yim HJ, Tak WY, Lee HJ, Sohn JH, Yoon KT, Kim IH, Kim HS, et al. Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: a randomised, non-inferiority, open trial. J Hepatol. 2014;61:792–98. doi:10.1016/j.jhep.2014.05.014. Epub 2014/05/23; PubMed PMID: 24845609.
   PubMed Web of Science ®Google Scholar
• Thursz MR, Richardson P, Allison M, Austin A, Bowers M, Day CP, Downs N, Gleeson D, MacGilchrist A, Grant A, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015;372:1619–28. doi:10.1056/NEJMoa1412278. Epub 2015/04/23; PubMed PMID: 25901427.
   PubMed Web of Science ®Google Scholar
• Szabo G, Mitchell M, McClain CJ, Dasarathy S, Barton B, McCullough AJ, Nagy LE, Kroll‐Desrosiers A, Tornai D, Min HA, et al. IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis. Hepatology. 2022;76:1058–68. doi:10.1002/hep.32478. Epub 20220602; PubMed PMID: 35340032.
   PubMedGoogle Scholar
• Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L, Dharancy S, Texier F, Hollebecque A, Serfaty L, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007;45:1348–54. doi:10.1002/hep.21607. PubMed PMID: 17518367.
   PubMed Web of Science ®Google Scholar
• Yannaki E, Athanasiou E, Fau - Xagorari A, Xagorari A, Fau - Constantinou V, Constantinou V, Fau - Batsis I, Batsis I, Fau - Kaloyannidis P, Kaloyannidis P, et al. G-CSF-primed hematopoietic stem cells or G-CSF per se accelerate recovery and improve survival after liver injury, predominantly by promoting endogenous repair programs. Exp Hematol., 2005;33:108–119. (0301-472X (Print)).
   PubMed Web of Science ®Google Scholar
• Gaia S, Smedile A, Omede P, Olivero A, Sanavio F, Balzola F, Ottobrelli A, Abate ML, Marzano A, Rizzetto M, et al. Feasibility and safety of G-CSF administration to induce bone marrow-derived cells mobilization in patients with end stage liver disease. J Hepatol. 2006;45:13–19. doi:10.1016/j.jhep.2006.02.018. Epub 20060406; PubMed PMID: 16635534.
   PubMed Web of Science ®Google Scholar
• Di Campli C, Zocco MA, Saulnier N, Grieco A, Rapaccini G, Addolorato G, Rumi C, Santoliquido A, Leone G, Gasbarrini G, et al. Safety and efficacy profile of G-CSF therapy in patients with acute on chronic liver failure. Dig Liver Dis. 2007;39:1071–76. doi:10.1016/j.dld.2007.08.006. Epub 2007/10/30; PubMed PMID: 17964871.
   PubMedGoogle Scholar
• Hou X, Li Y, Yuan H, Cai J, Liu R, Li J, Zhu C. Therapeutic effect and safety of granulocyte colony-stimulating factor therapy for acute-on-chronic liver failure: a systematic review and meta-analysis of randomized controlled trials. Front Med. 2021;8:784240. doi:10.3389/fmed.2021.784240. Epub 20211116; PubMed PMID: 34869505; PubMed Central PMCID: PMC8635095.
   PubMed Web of Science ®Google Scholar
• Vali L, Blazovics A, Feher J. The therapeutic effect of metadoxine on alcoholic and non-alcoholic steatohepatitis. Orv Hetil. 2005;146:2409–14. PubMed PMID: 16398154.
   PubMedGoogle Scholar
• Guerrini I, Gentili C, Nelli G, Guazzelli M. A follow up study on the efficacy of metadoxine in the treatment of alcohol dependence. Subst Abuse Treat Prev Policy. 2006;1:35. doi:10.1186/1747-597X-1-35. Epub 20061218; PubMed PMID: 17176456; PubMed Central PMCID: PMC1764726.
   PubMed Web of Science ®Google Scholar
• Verdon I, Spahr L, Serratrice J. N-acetylcysteine: effective treatment in severe alcoholic hepatitis? Rev Med Suisse. 2018;14:146–49. doi:10.53738/REVMED.2018.14.590.0146. PubMed PMID: 29341528.
   PubMedGoogle Scholar
• Amjad W, Alukal J, Doycheva I, Zhang T, Maheshwari A, Yoo H, Thuluvath PJ. A combination of N-Acetylcysteine and prednisone has No benefit over prednisone alone in severe alcoholic hepatitis: a retrospective analysis. Dig Dis Sci. 2020;65:3726–33. doi:10.1007/s10620-020-06142-4. Epub 20200218; PubMed PMID: 32072435.
   PubMed Web of Science ®Google Scholar
• Neuberger J. Public and professional attitudes to transplanting alcoholic patients. Liver Transpl. 2007;13:S65–8. doi:10.1002/lt.21337. PubMed PMID: 17969090.
   PubMed Web of Science ®Google Scholar
• Vaughn-Sandler V, Sherman C, Aronsohn A, Volk ML. Consequences of perceived stigma among patients with cirrhosis. Dig Dis Sci. 2014;59:681–86. doi:10.1007/s10620-013-2942-0. Epub 20131119; PubMed PMID: 24248421; PubMed Central PMCID: PMC3944010.
   PubMed Web of Science ®Google Scholar
• Lee MR, Leggio L. Management of alcohol use disorder in patients requiring liver transplant. Am J Psychiatry. 2015;172:1182–89. doi:10.1176/appi.ajp.2015.15040567. PubMed PMID: 26619772; PubMed Central PMCID: PMC4930850.
   PubMed Web of Science ®Google Scholar
• Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, Castel H, Duhamel A, Pageaux G-P, Leroy V, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med. 2011;365:1790–800. doi:10.1056/NEJMoa1105703. PubMed PMID: 22070476.
   PubMed Web of Science ®Google Scholar
• Marot A, Dubois M, Trépo E, Moreno C, Deltenre P, Herrero JI. Liver transplantation for alcoholic hepatitis: a systematic review with meta-analysis. PloS One. 2018;13:e0190823. doi:10.1371/journal.pone.0190823. Epub 20180111; PubMed PMID: 29324766; PubMed Central PMCID: PMC5764315.
   PubMed Web of Science ®Google Scholar
• DiMartini AF, Leggio L, Singal AK. Barriers to the management of alcohol use disorder and alcohol-associated liver disease: strategies to implement integrated care models. Lancet Gastroenterol Hepatol. 2022;7:186–95. doi:10.1016/s2468-1253(21)00191-6. PubMed PMID: 35026172.
   PubMed Web of Science ®Google Scholar